GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » Price-to-Owner-Earnings

Kontafarma China Holdings (HKSE:01312) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings Price-to-Owner-Earnings?

As of today (2024-06-06), Kontafarma China Holdings's share price is HK$0.036. Kontafarma China Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Kontafarma China Holdings's Price-to-Owner-Earnings or its related term are showing as below:

HKSE:01312' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.5   Med: 16.75   Max: 22.5
Current: 18

During the past 13 years, the highest Price-to-Owner-Earnings of Kontafarma China Holdings was 22.50. The lowest was 15.50. And the median was 16.75.


HKSE:01312's Price-to-Owner-Earnings is ranked better than
66.51% of 421 companies
in the Drug Manufacturers industry
Industry Median: 25.47 vs HKSE:01312: 18.00

As of today (2024-06-06), Kontafarma China Holdings's share price is HK$0.036. Kontafarma China Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01. Therefore, Kontafarma China Holdings's PE Ratio for today is At Loss.

As of today (2024-06-06), Kontafarma China Holdings's share price is HK$0.036. Kontafarma China Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was HK$-0.01. Therefore, Kontafarma China Holdings's PE Ratio without NRI for today is At Loss.

During the past 13 years, Kontafarma China Holdings's highest PE Ratio without NRI was 475.00. The lowest was 0.00. And the median was 60.00.


Kontafarma China Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Kontafarma China Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings Price-to-Owner-Earnings Chart

Kontafarma China Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 18.00

Kontafarma China Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 18.00

Competitive Comparison of Kontafarma China Holdings's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kontafarma China Holdings's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's Price-to-Owner-Earnings falls into.



Kontafarma China Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Kontafarma China Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.036/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kontafarma China Holdings  (HKSE:01312) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Kontafarma China Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Kontafarma China Holdings (HKSE:01312) Business Description

Traded in Other Exchanges
N/A
Address
30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.
Executives
Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui 2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z 2201 Interest of corporation controlled by you
China Health Management Investment Limited 2101 Beneficial owner
Waranty Assets Management (hk) Limited 2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines